Vertex Pharmaceuticals - VRTX Stock Forecast, Price & News

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Vertex Pharmaceuticals Trading Down 1.2 %

Shares of NASDAQ:VRTX opened at $299.23 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.50 and a quick ratio of 4.36. Vertex Pharmaceuticals has a 1 year low of $176.36 and a 1 year high of $305.95. The company has a market cap of $76.74 billion, a P/E ratio of 24.19, a PEG ratio of 2.18 and a beta of 0.45. The stock's fifty day moving average price is $281.84 and its 200-day moving average price is $264.59.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The pharmaceutical company reported $3.60 earnings per share for the quarter, beating analysts' consensus estimates of $3.12 by $0.48. Vertex Pharmaceuticals had a net margin of 38.26% and a return on equity of 31.22%. The company had revenue of $2.20 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter in the prior year, the firm earned $2.80 earnings per share. The firm's revenue for the quarter was up 22.5% compared to the same quarter last year. Sell-side analysts expect that Vertex Pharmaceuticals will post 12.56 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on VRTX shares. Wells Fargo & Company boosted their price target on shares of Vertex Pharmaceuticals from $300.00 to $305.00 in a research report on Friday, May 6th. Robert W. Baird lowered Vertex Pharmaceuticals from an "outperform" rating to a "neutral" rating and set a $250.00 target price for the company. in a research report on Friday, May 6th. Barclays lifted their price target on Vertex Pharmaceuticals from $291.00 to $307.00 and gave the company an "overweight" rating in a research report on Friday, August 5th. Piper Sandler increased their price objective on Vertex Pharmaceuticals from $256.00 to $288.00 and gave the stock a "neutral" rating in a report on Tuesday. Finally, Cowen boosted their target price on shares of Vertex Pharmaceuticals from $305.00 to $310.00 in a report on Monday, June 13th. Six equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $291.65.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CEO Reshma Kewalramani sold 11,689 shares of the business's stock in a transaction dated Friday, June 24th. The stock was sold at an average price of $291.30, for a total transaction of $3,405,005.70. Following the completion of the sale, the chief executive officer now owns 111,153 shares of the company's stock, valued at $32,378,868.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vertex Pharmaceuticals news, COO Stuart A. Arbuckle sold 22,173 shares of the firm's stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $303.93, for a total transaction of $6,739,039.89. Following the sale, the chief operating officer now directly owns 45,278 shares of the company's stock, valued at $13,761,342.54. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Reshma Kewalramani sold 11,689 shares of the company's stock in a transaction dated Friday, June 24th. The stock was sold at an average price of $291.30, for a total value of $3,405,005.70. Following the completion of the transaction, the chief executive officer now directly owns 111,153 shares of the company's stock, valued at approximately $32,378,868.90. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 208,520 shares of company stock valued at $59,937,985. Insiders own 0.40% of the company's stock.